Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.

Trial to begin enrolling in April; expected primary completion in mid-2027 -- Primary study endpoint of rate of major pathological response ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication ...

Eikon’s lead candidate EIK1001 is being investigated for melanoma in combination with MSD’s Keytruda in a Phase III trial.

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

From STAT’s Matthew Herper: Eikon Therapeutics, the cell-biology-focused startup run by former Merck R&D head Roger ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...

The World Health Organization raises alarms over increased West Bank violence affecting healthcare. In Congo, over 50 die due ...